Polymorphism at the glutathione S-transferase P1 locus as a risk factor for ifosfamide nephrotoxicity in children;Polimorfizm genu koduja̧cego transferazȩ S-glutationowa̧ klasy P1 jako czynnik ryzyka nefrotoksycznego działania ifosfamidu u dzieci

Polski Merkuriusz Lekarski

Volumn 14, Issue 82, 2003, Pages 295-298

  Zielińska, Elzbieta ^a   Zubowska, Małgorzata ^a   Bodalski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Children; Genotypes GSTs; Ifosfamide; Metabolism; Nephrotoxicity

Indexed keywords

ADENINE; DRUG METABOLITE; GLUTATHIONE S TRANSFERASE THETA1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GUANINE; IFOSFAMIDE; UNCLASSIFIED DRUG; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE T1; GSTP1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; ISOENZYME;

ADOLESCENT; AGE; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXCRETION; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLOMERULUS; HUMAN; KIDNEY FUNCTION; MALE; METABOLISM; METABOLITE; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; RISK FACTOR; SEX DIFFERENCE; URINARY EXCRETION; DRUG EFFECT; GENETICS; GLOMERULUS FILTRATION RATE; KIDNEY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GENOTYPE; GLOMERULAR FILTRATION RATE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0037698747     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boddy A. i wsp.: Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur. J. Cancer, 1996, 32A, 1179-1184.
2. Boddy A., Yule S.: Metabolism and pharmacokinetics of oxazaphoshorines. Clin. Pharmacokinet., 2000, 38, 291-304.
3. Brock N., Pohl J., Stekar J.: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer Clin. Oncol., 1981, 17, 1155-1163.
4. Bruggemann S., Kisro J., Wagner T.: Ifosfamide cytotoxicity on human tumor and renal cell: role of chloracetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res., 1997, 57, 2676-2680.
5. Dušinská M. i wsp.: Glutathione S-transferase polymorphisms influence the level of oxidative DNA damage and antioxidant protection in humans. Mut. Res., 2001, 482, 47-55.
6. Foxall P. i wsp.: Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide. Ther Drug Monit., 1996, 18, 498-505.
7. Gilard V. i wsp.: Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Cancer Chemother. Pharmacol, 1993, 31, 387-394.
8. Harries L. i wsp.: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis, 1997, 18, 641-644.
9. Helzlsouer K. i wsp.: Association between glulathione S-transferase M1, P1 and T1 genetic polymorphisms and development of breast cancer. J. Natl. Cancer Inst., 1989, 90, 512-518.
10. Johansson A. i wsp.: Structure - activity relationships and thermal stability of human glutathione transferase P1-1 governed by H-site residue 105. J. Mol. Biol., 1998, 278, 687-698.
11. Lin H.i wsp.: Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis, 1994, 15, 1077-1081.
12. Lind M. i wsp.: The effect of ifosfamide and its metabolites on intracellular glulathione levels in vitro and in vivo. Biochem. Pharmacol., 1989, 38, 1835-1840.
13. Misiura K., Zubowska M., Zielińska E.: Analysis of urinary excretion of ifosfamide and its side-chain metabolites in children with 31P NMR spectroscopy. Arzneim-Forsch/Drug Res. - praca przyjȩta do druku.
14. Nelson C. i wsp.: Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b]pyridine cytoxicity and DNA adduct formation in human prostate by glulathione S-transferase Pl. Cancer Res., 2001, 61, 103-109.
15. Nelson H. i wsp.: Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis, 1995, 16, 1243-1245.
16. Pratt C.: Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia. Semin. Oncol., 1990, 17, 31-40.
17. Raney B. i wsp.: Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am. J. Pediatr. Hematol. Oncol., 1994, 16, 286-295.
18. Ribrag V. i wsp.: Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia, 1996, 10, 1944-1949.
19. Rolfs A. i wsp.: Isolation of DNA from cells and tissue for PCR. In: PCR Clinical Diagnostics and Research (ed. Rolfs A.). Springer-Verlag. Berlin, Heidelberg. 1992, 84-85.
20. Rossi R. i wsp.: Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med. Pediatr. Oncol., 1994, 22, 27-32.
21. Russo D i wsp.: Coexpression of anionic glulathione S-transferase (GSTp) and multidrug resistance (mdr1) genes in acute myeloid and lymphoid leulemias. Leukemia, 1994, 8, 881-884.
22. Silies H. i wsp.: Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Int. J Clin. Pharmacol. Ther., 1998, 36, 246-252.
23. Skinner R. i wsp.: Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. Br. J. Cancer, 2000, 82, 1636-1645.
24. Tiirikainen M. i wsp.: Flow cytometric analysis of glutathione S-transferase-p in acute leukemia. Leukemia, 1994, 8, 978-984.
25. Wang Y. i wsp.: Cross-resistance and glutathione S-transferase-p levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res., 1989, 49, 6185-6192.
26. Watson M. i wsp.: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue activity and population frequency distribution Carcinogenesis, 1989, 19, 275-280.
27. Womer R.B.: Ifosfamide and paediatrics: should this marriage be saved? Eur. J. Cancer, 1996, 32A, 1100-1101.
28. Zhang H. i wsp.: Glutathione S-transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinoma. Int. J. Cancer (pred. Oncol), 1999, 84, 135-138.
29. Zielińska E., Bodalski J: Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in 3-year-old boy whose genotype reveal the genes encoding glutathione S-transferases GSTM1 and GSTT1. Cytobios, 2001, 106, 193-201.